0 NASDAQ Companies - June 14, 2020Pilgrim’s CEO on Paid Leave of AbsenceGREELEY, Colo., June 14, 2020 (GLOBE NEWSWIRE) — Pilgrim’s Pride Corporation (NASDAQ: PPC) today announced that president and CEO Jayson […]Read More
0 NASDAQ Companies - June 14, 2020Esperion Announces Pooled Analysis from Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL™ (Bempedoic Acid) Tablets Presented at the American Diabetes Association 80th Scientific SessionsANN ARBOR, Mich., June 14, 2020 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that pooled analysis from four Phase […]Read More
0 NASDAQ Companies - June 13, 2020Investigator-Initiated Study Shows Switching to Afrezza® Improves Glucose Control with No Additional Hypoglycemia in T2DMWESTLAKE VILLAGE, Calif., June 13, 2020 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD) announced that data from a new clinical […]Read More
0 NASDAQ Companies - June 13, 2020Lexicon Pharmaceuticals Presents Clinical Data at 80th American Diabetes Association Scientific SessionsTHE WOODLANDS, Texas, June 13, 2020 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today presented six posters for ZynquistaTM […]Read More
0 NASDAQ Companies - June 13, 2020vTv Therapeutics Presents Two Late-Breaking Poster Sessions on Simplici-T1 Study at the American Diabetes Association’s Virtual Sessions Supporting the Potential of TTP399 as First-in-Class Oral Adjunctive Therapy for Type 1 Diabetes Patients– Treatment with TTP399 resulted in significant improvements in HbA1c with reduction in insulin, without increasing risk of hypoglycemia or […]Read More
0 NASDAQ Companies - June 13, 2020Zealand Pharma presents elaborated results on the use of regular human insulin delivered by V-Go® in older adults with type 2 diabetes, at the 80th Scientific Sessions of the American Diabetes AssociationPress release – No. 08 / 2020Zealand Pharma presents elaborated results on the use of regular human insulin delivered by […]Read More
0 NASDAQ Companies - June 13, 2020Zosano Pharma to showcase new post-hoc analyses of Qtrypta’s (M207) clinical trial data comparing key efficacy results from the pivotal study and the open-label long term safety study on the 2020 American Headache Society’s Virtual Annual Scientific Meeting PlatformFREMONT, Calif., June 13, 2020 (GLOBE NEWSWIRE) — Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that new […]Read More
0 NASDAQ Companies - June 12, 2020DocuSign, Inc. to Join the NASDAQ-100 Index Beginning June 22, 2020NEW YORK, June 12, 2020 (GLOBE NEWSWIRE) — Nasdaq (Nasdaq: NDAQ) today announced that DocuSign, Inc. (Nasdaq: DOCU), will become […]Read More
0 NASDAQ Companies - June 12, 2020Fluidigm Files for FDA Emergency Use Authorization for Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Test for COVID-19Extraction-Free, Real-Time PCR Workflow with Capacity of Up to 6,000 Tests per DayEasy-to-Administer Saliva Test Would Eliminate Need for Invasive […]Read More
0 NASDAQ Companies - June 12, 2020Houston Wire & Cable Company Announces Governance, Management ChangesHOUSTON, June 12, 2020 (GLOBE NEWSWIRE) — Houston Wire & Cable Company (NASDAQ: HWCC) (the Company) today announced that Gary […]Read More